Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regent Pacific GroupRPGLF 14 3-Year EPS without NRI Growth Rate is 59.80% as of Dec. 2025, which is 106% above its 10-year median of 29.00. GuruFocus rates RPGLF with a GF Score™ of 14/100. The stock has 6 warning signs investors should review. Among 786 Drug Manufacturers companies, Regent Pacific Group ranks better than 91.09% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 59.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 47.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Regent Pacific Group was 240.80% per year. The lowest was -53.50% per year. And the median was 29.00% per year.
Regent Pacific Group (OTCPK:RPGLF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Regent Pacific Group 3-Year EPS without NRI Growth Rate Related Terms
RPGLF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regent Pacific Group 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Regent Pacific Group's 3-Year EPS without NRI Growth Rate falls into.
Regent Pacific Group 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 59.80% mean?
Regent Pacific Group (RPGLF) has a 3-Year EPS without NRI Growth Rate of 59.80% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Regent Pacific Group and its competitors. This is 106% above median its historical median of 29.00. According to the industry distribution chart, Regent Pacific Group ranks #70 out of 786 companies in the Drug Manufacturers industry, placing it in the top 8.9%.
Is Regent Pacific Group's 3-Year EPS without NRI Growth Rate too high?
Regent Pacific Group's current 3-Year EPS without NRI Growth Rate of 59.80% is 106% above median its 10-year median of 29.00. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.90. Regent Pacific Group's value of 59.80% is 504% above this industry median. Based on the distribution chart, Regent Pacific Group ranks #70 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Regent Pacific Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #70 out of 786 companies for 3-Year EPS without NRI Growth Rate. This places Regent Pacific Group in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.90. Regent Pacific Group's value of 59.80% is 504% above this benchmark. While the company's 10-year median is 29.00 vs. the industry median of 9.90, Regent Pacific Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.90, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regent Pacific Group's current 3-Year EPS without NRI Growth Rate of 59.80% is 504% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Regent Pacific Group and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current 3-Year EPS without NRI Growth Rate is 59.80%, which is 106% above median its own 10-year median of 29.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current 3-Year EPS without NRI Growth Rate of 59.80%. The current 3-Year EPS without NRI Growth Rate is 59.80%, which is 106% above median its 10-year median of 29.00 and 504% above the Drug Manufacturers industry median of 9.90. Regent Pacific Group's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current 3-Year EPS without NRI Growth Rate is 59.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
14GF Score
Get the complete analysis for RPGLF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPGLF has been successfully added to your 
